Angeles
Castro Iglesias
Hospital Universitario La Fe
Valencia, EspañaPublications in collaboration with researchers from Hospital Universitario La Fe (11)
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
2019
2018
-
Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study
American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522
2017
-
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311
-
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4
Liver International, Vol. 37, Núm. 12, pp. 1823-1832
2016
-
Altered underlying renal tubular function in patients with chronic hepatitis B receiving nucleos(t)ide analogs in a real-world setting the MENTE study
Journal of Clinical Gastroenterology, Vol. 50, Núm. 9, pp. 779-789
-
Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma
Hepatology, Vol. 63, Núm. 2, pp. 488-498
2015
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
2012
-
Long-term benefits of nevirapine-containing regimens: Multicenter study with 506 patients, followed-up a median of 9 years
Current HIV Research, Vol. 10, Núm. 6, pp. 513-520
2009
-
The Spanish HIV BioBank: A model of cooperative HIV research
Retrovirology, Vol. 6
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092